55 results
8-K
EX-99.2
ABOS
Acumen Pharmaceuticals Inc
14 May 24
Acumen Pharmaceuticals Reports First Quarter 2024 Financial Results and Business Highlights
7:35am
idiotype mAb) 13 Target Engagement Assessed by Measuring Sabirnetug-AO Complex in CSF AO selective detection (anti-A mAb) Only Sabirnetug-AO … complex is measurable Novel assay configuration tailored to selectively detect sabirnetug-AβO complex in CSF as direct measure of target engagement
8-K
EX-99.1
ABOS
Acumen Pharmaceuticals Inc
14 May 24
Acumen Pharmaceuticals Reports First Quarter 2024 Financial Results and Business Highlights
7:35am
engagement analyses from the Phase 1 INTERCEPT-AD study in AD at the American Academy of Neurology Annual Meeting.
◦The results build upon Acumen’s … humanized monoclonal antibody to clinically demonstrate selective target engagement of synaptotoxic AβOs. Additional information can be found here.
In April
8-K
EX-99.1
p3inqs hgbv
26 Mar 24
Results of Operations and Financial Condition
7:42am
8-K
EX-99.1
ozo2c9ivm
19 Mar 24
Corporate Presentation March 2024 1
8:05am
8-K
EX-99.1
up69hm
12 Jan 24
Corporate Presentation January 2024 1
8:42am
8-K
EX-99.1
ifl1f 1j3z
8 Jan 24
Regulation FD Disclosure
8:33am
8-K
EX-99.1
wijikjpp
4 Dec 23
Corporate Presentation December 2023 1
7:45am
8-K
EX-99.1
liq 3mkvn
13 Nov 23
Corporate Presentation November 2023 1
5:10pm
8-K
EX-99.1
ow2wynhs1 lnfp6
13 Nov 23
Acumen Pharmaceuticals Reports Third Quarter 2023 Financial Results and Business Highlights
7:20am
8-K
EX-99.2
77k9uzq3
8 Aug 23
Acumen Pharmaceuticals Reports Second Quarter 2023 Financial Results and Business Highlights
7:33am
8-K
EX-99.1
qc0 x2uyp
8 Aug 23
Acumen Pharmaceuticals Reports Second Quarter 2023 Financial Results and Business Highlights
7:33am
424B5
uty 3e3ocigi31
20 Jul 23
Prospectus supplement for primary offering
4:11pm
424B5
6edcscq3u b88
17 Jul 23
Prospectus supplement for primary offering
4:49pm
8-K
tx4v7uzr3noapvs43
17 Jul 23
Acumen Pharmaceuticals Presents Positive Topline Results from First-in-Human
6:06am
8-K
EX-99.1
j6x7ec502ot
17 Jul 23
Acumen Pharmaceuticals Presents Positive Topline Results from First-in-Human
6:06am